SpyGlass Pharma, Inc. (SGP) Stock Forecast
SGP analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.83 / 5 from 6 analysts
- Price target
- $44.00 average of analyst targets
- Upside to target
- +83.3% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.66
- 52-week range
- $17.56 – $29.68
SGP analyst ratings
6 analystsNumber of analysts at each rating.
SGP price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SGP earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.62 | −$0.71 | −$0.52 | — | — | 6 |
| Current fiscal year (2026) | −$2.50 | −$2.57 | −$2.31 | −$1.96 | −27.5% | 6 |
| Next fiscal year (2027) | −$2.81 | −$3.45 | −$1.95 | −$2.50 | −12.6% | 6 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SGP revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | — | 5 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 5 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 5 |
SGP EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SGP EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.58 | −$0.62 | −$0.62 | −$0.62 | −$0.62 | +6.8% | 0 up · 1 down |
| Current fiscal year (2026) | −$2.31 | −$2.45 | −$2.48 | −$2.48 | −$2.50 | +8.0% | 0 up · 1 down |
| Next fiscal year (2027) | −$2.70 | −$2.68 | −$2.72 | −$2.72 | −$2.81 | +4.3% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SGP earnings surprises
Reported EPS vs the consensus estimate for the last 3 quarters; SGP beat in 1 of 3.
What analysts expect from SGP
6 analysts cover SpyGlass Pharma; their consensus rating is strong buy (4.83 on a 1–5 scale, where 5 is a strong buy). The average price target is $44.00, 83.3% above the latest close of $24.00. Analysts expect earnings of −$2.50 per share for 2026, −27.5% from a year earlier. For 2027 the average estimate is −$2.81 per share. SpyGlass Pharma beat the EPS estimate in 1 of the last 3 quarters.
Related: SGP income statement, SGP key metrics, SGP chart. See the SGP stock overview for the latest quote and news.
SGP forecast FAQ
What is SpyGlass Pharma's price target?
The average analyst price target for SpyGlass Pharma is $44.00, 83.3% above the latest close of $24.00.
Is SpyGlass Pharma a buy, hold or sell?
Of 6 analysts covering SpyGlass Pharma, 5 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is SpyGlass Pharma's EPS forecast?
Analysts forecast −$2.50 per share for 2026 (range −$2.57 to −$2.31); for 2027 the estimate is −$2.81.
When does SpyGlass Pharma report earnings?
SpyGlass Pharma is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.66.
Does SpyGlass Pharma usually beat earnings estimates?
SpyGlass Pharma reported EPS at or above the analyst estimate in 1 of the last 3 quarters.